Next Article in Journal
Clinical Utility of Second-Look FDG PET-CT to Stratify Incomplete Metabolic Response Post (Chemo) Radiotherapy in Oropharyngeal Squamous Cell Carcinoma
Next Article in Special Issue
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions
Previous Article in Journal
Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics
Previous Article in Special Issue
PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 2
10.3390/cancers15020463
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral

by
Takayuki Matsumae
1,†,
Takahiro Kodama
1,†,
Yuki Tahata
1,
Yuta Myojin
1,2,
Akira Doi
1,
Akira Nishio
1,
Ryoko Yamada
1,
Yasutoshi Nozaki
3,
Masahide Oshita
4,
Naoki Hiramatsu
5,
Naoki Morishita
6,
Kazuyoshi Ohkawa
7,
Taizo Hijioka
8,
Mitsuru Sakakibara
9,
Yoshinori Doi
10,
Naruyasu Kakita
11,
Takayuki Yakushijin
12,
Ryotaro Sakamori
13,
Hayato Hikita
1,
Tomohide Tatsumi
1 and
Tetsuo Takehara
1,*add Show full author list remove Hide full author list
1
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
2
Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
3
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki 660-8511, Japan
4
Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda 563-0025, Japan
5
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai 591-8501, Japan
6
Department of Gastroenterology and Hepatology, Minoh City Hospital, Minoh 562-8562, Japan
7
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan
8
Department of Gastroenterology and Hepatology, National Hospital Organization Osaka Minami Medical Center, Kawachinagano 586-8521, Japan
9
Department of Gastroenterology and Hepatology, Yao Municipal Hospital, Yao 581-0069, Japan
10
Department of Gastroenterology and Hepatology, Otemae Hospital, Osaka 540-0008, Japan
11
Department of Gastroenterology and Hepatology, Kaizuka City Hospital, Kaizuka 597-0015, Japan
12
Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka 558-8558, Japan
13
Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka 540-0006, Japan
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2023, 15(2), 463; https://doi.org/10.3390/cancers15020463
Submission received: 3 December 2022 / Revised: 4 January 2023 / Accepted: 10 January 2023 / Published: 11 January 2023
(This article belongs to the Collection Primary Liver Cancer)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

Secreted glycoprotein thrombospondin-2 (TSP-2) is a predictive biomarker of hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after HCV elimination by direct-acting antiviral agents (DAAs). The AFT score using TSP-2, AFP, and the FIB-4 index may identify those who require HCC surveillance.

Abstract

We evaluated the value of secreted glycoprotein thrombospondin-2 (TSP-2) to predict hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after Hepatitis C virus (HCV) elimination by direct-acting antiviral agents (DAAs). A total of 786 CHC patients without an HCC history who achieved a sustained virological response (SVR) with DAAs were randomly assigned 2:1, with 524 patients as the derivation cohort and 262 patients as the validation cohort. Serum TSP-2 levels at the end of treatment were measured by enzyme-linked immunosorbent assay (ELISA). In the derivation cohort, the cumulative HCC rate was significantly higher in the high TSP-2 group than in the low TSP-2 group. Multivariate Cox proportional hazards analysis revealed that TSP-2, α-fetoprotein (AFP), and the fibrosis-4 (FIB-4) index were independent HCC risk factors. The area under the receiver operating characteristic curve (AUROC) of the score calculated from these three factors (AFT score) for predicting HCC was 0.83, which was significantly higher than that of each factor alone (TSP-2: 0.70, AFP: 0.72, FIB-4: 0.69). The AFT score was used to stratify patients according to the risk of HCC occurrence in the validation cohort. Lastly, in patients with a FIB-4 index < 3.25, the serum TSP-2 levels could be used to identify those patients with a high risk of HCC occurrence. Serum TSP-2 levels are a predictive biomarker of HCC occurrence in CHC patients after HCV elimination by DAA treatment. The AFT score using TSP-2, AFP, and the FIB-4 index may identify those who require HCC surveillance.
Keywords:
TSP-2; HCC; HCV; DAA; THBS2

1. Introduction

Direct-acting antiviral agents (DAAs) have become a standard treatment for hepatitis C virus (HCV) infection and can eradicate HCV with a more than 95% success rate regardless of the HCV genotype or host liver fibrosis status. HCV eradication is known to improve liver function and reduce the risk of hepatocellular carcinoma (HCC) occurrence [1,2] but cannot completely eliminate the risk of HCC development [3]. The molecular mechanisms of HCC development in DAA-cured sustained virological response (SVR) patients are not fully understood. However, the accumulation of genomic abnormalities, liver fibrosis, and cellular dysfunction caused by long-term persistent HCV infection remain after HCV elimination and may contribute to HCC development [4]. Comorbidities such as diabetes mellitus (DM) and concomitant liver injury caused by excess alcohol intake or nonalcoholic steatohepatitis (NASH) may also promote hepatocarcinogenesis [5]. Therefore, it is important to identify patients who have a high risk of HCC occurrence even after achievement of SVR by DAA treatment and to perform appropriate HCC surveillance [6].
It is frequently reported that patients with liver cirrhosis (F4) are at high risk of developing HCC [7,8], and the guidelines of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Disease (AASLD) recommend surveillance after viral eradication in patients with a fibrosis-4 (FIB-4) index > 3.25 who are considered to have cirrhosis [9]. However, although less frequent than in patients with a FIB-4 index > 3.25, HCC also occurs in patients with a FIB-4 index < 3.25 [7]. Indeed, the EASL recommends HCC surveillance for patients with advanced fibrosis (F3), but no circulating biomarkers have been proposed to identify those patients [10]. Therefore, it is desirable to develop better predictive biomarkers that can identify SVR patients with a high risk for HCC occurrence among noncirrhotic patients.
TSP-2, a member of the thrombospondin family, is a matricellular glycoprotein that mediates cell-to-cell and cell-to-matrix interactions [2]. We have recently reported that serum TSP-2 is a novel biomarker for identifying NASH, advanced fibrosis, and HCC occurrence among nonalcoholic fatty liver disease (NAFLD) patients [11]. In the present study, we examined the utility of serum TSP-2 as a biomarker of HCC occurrence in CHC patients who achieved SVR by DAA treatment.

2. Materials and Methods

2.1. Study Population

We conducted a prospective multicenter cohort study that enrolled 2840 CHC patients who underwent DAA treatment from September 2014 to December 2017 at Osaka University Hospital and 13 related hospitals. We excluded patients who were coinfected with human immunodeficiency virus or hepatitis B virus, suffered from primary bile cholangitis or autoimmune hepatitis, or were under 20 years old, or had undergone liver transplantation from the registration. Written informed consents were obtained from all patients, and the protocol of this study was reviewed and approved by the institutional review board (IRB) committees of Osaka University Hospital and all participating hospitals. IRB No of this study is 17032. This study complies with the Helsinki Declaration.

2.2. Regimens of DAA Treatment

The DAA treatment regimens were as follows: 24 weeks of daclatasvir and asunaprevir (DCV/ASV); 12 weeks of ombitasvir, paritaprevir and ritonavir (OBV/PTV/ritonavir), ledipasvir and sofosbuvir (LDV/SOF), elbasvir and grazoprevir (EBR/GZR), and SOF and ribavirin (SOF/RBV). We defined SVR as an undetectable serum HCV ribonucleic acid (RNA) level at 24 weeks after the end of treatment. All patients were treated according to the Japanese guidelines for the treatment of chronic HCV infection.

2.3. Patient Follow-Up

As surveillance for HCC, all patients in this study underwent abdominal ultrasonography, CT scan, or magnetic resonance imaging (MRI) every six months after the end of treatment (EOT) according to the recommendation of the Japan Society of Hepatology. The laboratory data including standard markers measured in clinical practice of chronic liver disease were collected in this study at the point of EOT (the HCV-RNA level was only measured at the pretreatment). The observation period started on the day that DAA treatment ended. The end point of the observation was the date when HCC occurred. In patients who never developed HCC, the date of the most recent liver imaging test was the last date of the observation period.

2.4. Enzyme-Linked Immunosorbent Assay (ELISA) of Serum TSP-2

The sera of patients registered in this study were stored in a −80 °C freezer at Osaka University. The serum TSP-2 level was examined with an ELISA kit for human TSP-2 (Catalog#DTSP20, R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instruction. The absorbance was examined by a Varioskan LUX (Thermo Scientific, Waltham, MA, USA).

2.5. Statistical Analysis

Statistical analysis was performed with Student’s t-test for comparing parametric values or the Mann–Whitney U test when comparing nonparametric values. For multiple comparisons, One-way ANOVA, followed by Tukey’s multiple comparisons test, was performed. The Kaplan–Meier curves were drawn and a log-rank test was performed to examine differences in the cumulative HCC occurrence rates. Kaplan–Meier curves were constructed using the period from the EOT date to the HCC occurrence date or the period from the EOT date to the death date or the last date of HCC surveillance. To examine the factors associated with HCC occurrence, univariate and multivariate Cox proportional hazards models were used. We used GraphPad Prism ver. 9.2.0 for Macintosh for data analysis and creating graphs.

3. Results

3.1. Serum TSP-2 Levels Are Capable of Identifying CHC Patients Who Have a High Risk of HCC Development after HCV Elimination by DAA Treatment

To evaluate the value of serum TSP-2 levels for predicting HCC occurrence in CHC patients who achieved SVR with DAAs, we selected 786 patients who fulfilled the following criteria from our multicenter prospective observational cohort: those with SVR achievement, those with complete medical records, those without a past HCC history, and those who provided agreement for serum storage (Supplementary Figure S1). The patients were randomly assigned 2:1, with 524 patients as the derivation cohort and 262 patients as the validation cohort. In the derivation cohort, the median age was 70 years, and the percentage of males was 38.9% (Table 1). The percentage of genotype 1 was 77.5%, and the median platelet count was 16.8 × 104/μL (Table 1).
A total of 24 patients (4.6%) developed HCC during the 41.5-month median observation period, and the cumulative HCC rate after DAA treatment was 2.7% at 2 years and 4.9% at 4 years (Figure 1A). The patients with HCC (HCC+ group) showed significantly lower levels of platelets and albumin and higher levels of total bilirubin, hyaluronic acid, AFP and the FIB-4 index than those without HCC (HCC− group) (Table 1). The serum TSP-2 levels were significantly higher in the HCC+ group than in the HCC− group (Figure 1B). The AUROC of the serum TSP-2 level for predicting HCC was 0.70 in the derivation cohort (Figure 1C). We then split the patients into two groups based on the cutoff value of the serum TSP-2 level (86.954 ng/µL) determined by the Youden index of the ROC curve. The cumulative HCC rate was significantly higher in the high TSP-2 group (11.4% at 2 years and 14.1% at 4 years) than in the low TSP-2 group (0.9% at 2 years and 3.0% at 4 years) (Figure 1D). These data indicated that serum TSP-2 levels can be used to identify CHC patients who have a high risk of HCC development after HCV elimination by DAA treatment.

3.2. Serum TSP-2 Levels Reflect Liver Fibrosis and Inflammation in CHC Patients after HCV Elimination by DAA Treatment

We next examined the clinical factors associated with serum TSP-2 levels in the derivation cohort. The serum TSP-2 levels were significantly higher in the patients with F3-4 stages than in the patients with F0-2 stages (Figure 2A) and showed a significant positive association with serum hyaluronic acid (HA) levels, a well-known fibrosis marker (Figure 2B, Supplementary Table S1), suggesting that serum TSP-2 levels reflect liver fibrosis. In addition, the serum TSP-2 level was also positively associated with serum AST and ALT levels (Figure 2C,D, Supplementary Table S1), suggesting that serum TSP-2 levels also reflect liver inflammation. These data were consistent with our previous findings that serum TSP-2 levels reflect liver injury and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) [11].

3.3. The AFT Score Composed of AFP, TSP-2 and the FIB-4 Index Stratifies Patients According to the HCC Risk after DAA Treatment

We next sought to identify predictive factors of HCC development in CHC patients after HCV elimination by DAA treatment. In the derivation cohort, univariate analysis using the Cox proportional hazards model identified AFP, the FIB-4 index, and TSP-2 as factors contributing to HCC occurrence (p < 0.01) (Table 2). Multivariate analysis showed that all three factors were significant independent predictors of HCC development in this cohort (Table 2).
The AUROCs of AFP and the FIB-4 index to predict HCC occurrence were 0.72 and 0.69, respectively (Figure 3A,B). The predictive power for HCC occurrence was not significantly different among AFP, the FIB-4 index, and TSP-2 (Figure 3C). We thus created a new score (AFT score) composed of these independent predictive factors (AFP, FIB-4 index, and TSP-2) and evaluated its predictive potential. The formula of the AFT score is ‘−5.498859067 + 0.0144285182 × (TSP-2) + 0.2617308791 × (FIB-4 index) + 0.0870554852 × (AFP)’. The AFT score showed an AUROC of 0.81, which was significantly higher than that of each individual factor (Figure 3C). The sensitivity and specificity of the AFT score for predicting HCC occurrence were 0.727 and 0.792, respectively (Figure 3C). The cumulative HCC rate was significantly higher in the high AFT score group (8.6% at 2 years and 13.5% at 4 years) than in the low AFT score group (0.5% at 2 years and 1.9 at 4 years) (Figure 3D). Time-dependent ROC analysis showed that the AUROC value of the AFT score was consistently high for predicting the 1-, 2-, 3-, and 4-year occurrence of HCC (AUROC; 0.801, 0.840, 0.816, and 0.783, respectively) (Supplementary Figure S2). Taken together, the AFT scores stratified patients according to their HCC risk after DAA treatment.

3.4. The TSP-2 and AFT Scores Stratified Patients According to HCC Risk in the Validation Cohort

We then evaluated the predictive value of AFT score as well as serum TSP-2 level in the validation cohort. In the validation cohort, the median age was 68 years, and the percentage of males was 34.7% (Supplementary Table S2). A total of 19 patients (7.3%) developed HCC during the 43.6-month median observation period, and the cumulative HCC rate after DAA treatment was 3.4% at 2 years and 9.1% at 4 years (Supplementary Table S2, Figure 4A). There was no significant difference in HCC occurrence during the observation period between the derivation and validation cohorts. The patients with HCC occurrence (HCC+ group) showed significantly lower platelet counts, lower levels of WBCs, HCV-RNA, and albumin and higher levels of age, total bilirubin, hyaluronic acid, AFP and the FIB-4 index than those without HCC occurrence (HCC− group) (Supplementary Table S2). The serum TSP-2 levels were significantly higher in the HCC+ group than in the HCC− group (Figure 4B). When we stratified the patients based on the same cutoff value of serum TSP-2 level as determined in the derivation cohort, the cumulative HCC rate was significantly higher in the high TSP-2 group (10.7% at 2 years and 19.3% at 4 years) than in the low TSP-2 group (2.6% at 2 years and 8.1% at 4 years) (Figure 4C). Similarly, the AFT score can also be used to stratify the risk of HCC occurrence after DAA therapy in the validation cohort. The cumulative HCC occurrence rate in the AFT score high group was 9.7% at 2 years and 19.0% at 4 years, while the cumulative HCC occurrence rate in the AFT score low group was 1.5% at 2 years and 6.5% at 4 years (Figure 4D). Taken together, TSP-2 and AFT scores can be used to stratify the patients based on the risk of HCC occurrence in the validation cohort.

3.5. Serum TSP-2 Level Identifies Patients with a High Risk of HCC Occurrence among Patients with FIB-4 Index < 3.25

According to the EASL guidelines, active routine surveillance is not recommended for the group with a FIB-4 index less than 3.25 because their livers are not highly fibrotic and they are at a lower risk of developing HCC in the future [10]. However, even among the 587 patients with a FIB-4 index less than 3.25 in our entire cohort, 19 patients developed HCC during the median 42.4-month observation period, suggesting the importance of developing biomarkers to identify these patients. We thus finally evaluated the potential value of TSP-2 to identify those patients. The cumulative HCC occurrence rate in the high serum TSP-2 group was 7.6% at 2 years and 9.4% at 4 years, while the cumulative HCC occurrence rate in the low serum TSP-2 group was 1.0% at 2 years and 3.3% at 4 years (Figure 5). Collectively, serum TSP-2 levels could identify patients with a FIB-4 index less than 3.25 who may have a high risk of developing HCC.

4. Discussion

TSP-2 is a member of the thrombospondin family, which is known to be a matricellular glycoprotein that regulates cell-to-cell and cell-to-matrix interactions [12]. Thrombospondins are known to be involved in tissue repair, angiogenesis, connective tissue organization, and so on [12]. TSP-2 is secreted from the fibrotic liver, and we have recently reported that serum TSP-2 is a novel biomarker for detecting NASH, advanced fibrosis, and predicting HCC occurrence among nonalcoholic fatty liver disease (NAFLD) patients [11]. Similar findings were also reported from two different labs, indicating the validity of TSP-2 as a useful biomarker to determine the activity and fibrosis stage of NAFLD [13,14]. On the other hand, the potential of TSP-2 as a biomarker to predict future HCC occurrence among CHC patients who had HCV eliminated by DAA treatment has never been investigated. In this study, we first examined the serum TSP-2 levels at the end of DAA treatment in 524 CHC patients in the derivation cohort and found that the serum TSP-2 levels were significantly higher in the patients who later developed HCC than in those who did not. We subsequently showed that the serum TSP-2 levels predicted HCC occurrence with an AUROC of 0.7 and thus was used to stratify DAA-treated patients according to the risk of HCC occurrence. Similar results were confirmed in the validation cohort. Moreover, even among the possible noncirrhotic patients selected by a FIB-4 index < 3.25, serum TSP-2 levels were used to stratify patients according to the risk of HCC occurrence. We thus reported here for the first time the usefulness of serum TSP-2 levels in identifying CHC patients who have a high risk of HCC development after HCV elimination by DAA treatment. In the current study, consistent with the results from our previous NAFLD study [11], we found that serum TSP-2 levels were correlated with markers of liver fibrosis and injury, which account for both accumulated and incoming HCC risk, respectively, leading to the high potential to predict HCC occurrence even after HCV eradication.
Several biomarkers available in daily practice have been reported to be able to predict future HCC development after DAA treatment. Liver fibrosis stage is obviously one of the most important predictors for HCC occurrence after DAA treatment [15]. The FIB-4 index, a noninvasive test composed of AST, ALT, platelets and age, can be used to predict the stage of liver fibrosis and has been shown to be a predictive marker of HCC occurrence in patients with a variety of liver diseases [16,17,18,19]. Several groups recently reported that a FIB-4 index higher than 3.25 could be used to identify a high-risk population of CHC patients after SVR secondary to DAA treatment, both in the presence and absence of cirrhosis [20,21,22,23]. Based on these observations, both the EASL and AASLD guidelines recommended HCC surveillance after SVR in patients with a FIB-4 > 3.25 [9,10]. Alpha fetoprotein (AFP) is a well-known diagnostic and prognostic biomarker used clinically for HCC, and a recent study revealed that posttreatment AFP levels could be used to predict HCC occurrence in advanced chronic liver disease from European and Japanese patients who achieved SVR after DAA treatment [20,21,24]. In our current study, consistent with these previous reports, the FIB-4 index and AFP, as well as TSP-2, were also both independent predictors of HCC occurrence. However, the AUROCs of these factors were still approximately 0.7, facilitating the establishment of a new combined scoring system named the AFT score with AFP, FIB-4 index and TSP-2. Our new score predicted HCC occurrence at an AUROC of 0.81, which was significantly higher than that of each individual factor, with good sensitivity (0.727) and specificity (0.792) in the derivation cohort. We also confirmed that the AFT score was capable of discriminating patients with a high risk of developing HCC in the validation cohort. Importantly, the time-dependent ROC analysis showed that the AUROCs of the AFT score predicting HCC occurrence were consistently high throughout the 4-year observation period, indicating the robustness of this predictive biomarker.
Several new serum biomarkers to predict HCC occurrence have also been investigated at the preclinical stage [25]. Nagata H et al. predicted HCC occurrence in CHC patients treated with DAA by measuring the posttreatment levels of serum Wisteria floribunda agglutinin positive Mac-2 binding protein (WFA + M2BP) [26]. WFA + -M2BP is secreted from hepatic stellate cells (HSCs) and promotes their extracellular matrix production via interaction with Mac2-expressing Kupffer cells, possibly contributing to a supportive microenvironment for HCC growth [27]. Although the cohort size was very small, Debes J.D. et al. measured pretreatment serum levels of a variety of immune mediators in CHC patients who underwent DAA therapy, showing that nine cytokines, including MIG, IL22, TRAIL, APRIL, VEGF, IL3, TWEAK, SCF and IL21, could identify the patients who developed de novo HCC with an AUROC > 0.8 [28]. Growth differentiation factor 15 (GDF15) is a cytokine induced by oxidative stress or mitochondrial dysfunction, and we have reported that serum GDF15 predicts HCC occurrence after DAA treatment [29]. Meanwhile, all these markers, including ours, are still in the exploratory phases, and none of these markers have been prospectively validated. Therefore, further accurate prospective evaluations of these biomarkers need to be performed in parallel to select the best candidate for clinical practice.
The limitations of this study are as follows: (1) our research design is a retrospective study, (2) there is no racial diversity, (3) the observation period is still relatively short (a 41.5 months median observation period), (4) information of some potentially important clinical variables is missing (e.g., alcohol consumption and smoking habit) and (5) we only evaluated the utility of serum TSP-2 levels at the end of DAA treatment. Thus, the utility of serum TSP-2 levels long after SVR should be evaluated in the future. In addition, most of the patients underwent only abdominal ultrasonography for HCC surveillance at the enrollment of this study, so we did not exclude the possibility that small HCC already existed especially in patients who developed HCC within 6 months of follow-up. To address this concern, we excluded the patients who developed HCC within 6 months after DAA treatments from the entire cohort. Even in this cohort, serum TSP-2 levels were also significantly higher in patients who had developed HCC than in patients who had not developed HCC (Supplementary Figure S3A). TSP-2, AFP, and the FIB-4 index were independent risk factors for predicting HCC occurrence after DAA treatments. The AUROC of the AFT score for predicting HCC occurrence was higher than that of TSP-2, AFP, and the FIB-4 index (Supplementary Figure S3B). HCC occurrence rate was significantly higher in patients with high TSP-2 levels or high AFT scores than that in patients with low TSP-2 levels or low AFT scores, respectively (Supplementary Figure S3C). Taken together, we believe that TSP-2 and AFT score may be useful for the prediction of de novo HCC occurrence of CHC patients after DAA treatment.

5. Conclusions

Serum TSP-2 levels are a predictive biomarker of HCC occurrence in CHC patients after HCV elimination by DAA treatment. The AFT score using TSP-2, AFP, and the FIB-4 index may identify those who require HCC surveillance.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers15020463/s1, Figure S1: 786 patients who fulfilled the following criteria from our multicenter prospective observational cohort: those with SVR achievement, those with complete medical records, those without a past HCC history, and those who provided agreement for serum storage, Figure S2: Time-dependent ROC of the occurrence of HCC 1-, 2-, 3-, and 4-year after DAA treatment, Figure S3: Analysis of the cohort without patients who developed HCC within 6 months of follow-up, Table S1: Correlation coefficient between TSP-2 and other clinical variables in the derivation cohort, Table S2: Characteristics of patients in the validation cohort.

Author Contributions

Conceptualization, writing, review, and editing: T.M. and T.K.; Data curation and formal analysis: T.M., T.K., Y.T. and R.S.; Methodology and data curation: Y.M., A.D., A.N., Y.T., R.Y., H.H. and T.T. (Tomohide Tatsumi); Funding acquisition: T.K. and T.T. (Tetsuo Takehara); Project administration and supervision: T.T. (Tetsuo Takehara); Resources: Y.N., M.O., N.H., N.M., K.O., T.H., M.S., Y.D., N.K. and T.Y. All authors have read and agreed to the published version of the manuscript, agreed to be accountable for all aspects of the work and ensured that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Funding

This work was supported by the Japan Agency for Medical Research and Development (AMED) under grant numbers JP22fk0210074 (T.K.), JP22fk0210091 (T.K.), JP22fk0210110 (T.K.), JP22ama221410 (T.K.), JP22fk0210064 T.T. (Tetsuo Takehara) and by a Grant-in-Aid for Scientific Research (T.K.) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, under grant number 20H03661.

Institutional Review Board Statement

The study protocol was approved by the institutional review board (IRB) committees of Osaka University Hospital and all participating hospitals (IRB No. 17032).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

The authors thank the other participating hospitals for this study, including Toyonaka Municipal Hospital, Itami City Hospital, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya Municipal Central Hospital, Suita Municipal Hospital, Sumitomo Hospital, and Daini Osaka Police Hospital.

Conflicts of Interest

Tetsuo Takehara received grants from Gilead Sciences, Inc., MSD K. K. and AbbVie, Inc. and is on the speakers’ bureau for Gilead Sciences, Inc., MSD K. K. and AbbVie, Inc. Hayato Hikita is on the speakers’ bureau for Gilead Sciences, Inc. and AbbVie, Inc. Takahiro Kodama received grants from AbbVie, Inc. and Gilead Sciences, Inc., and is on the speakers’ bureau for Gilead Sciences, Inc., MSD K. K. and AbbVie, Inc. All other authors declare that they have no conflict of interest to disclose.

References

  1. Kanwal, F.; Kramer, J.R.; Asch, S.M.; Cao, Y.M.; El-Serag, H.B. Longer Term Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents. Hepatology 2018, 68, 521A. [Google Scholar]
  2. Ioannou, G.N.; Green, P.K.; Berry, K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J. Hepatol. 2018, 68, 25–32. [Google Scholar] [CrossRef] [PubMed]
  3. Janjua, N.Z.; Chong, M.; Kuo, M.; Woods, R.; Wong, J.; Yoshida, E.M.; Sherman, M.; Butt, Z.A.; Samji, H.; Cook, D.; et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J. Hepatol. 2017, 66, 504–513. [Google Scholar] [CrossRef] [PubMed]
  4. Ioannou, G.N. HCC surveillance after SVR in patients with F3/F4 fibrosis. J. Hepatol. 2021, 74, 458–465. [Google Scholar] [CrossRef] [PubMed]
  5. D’Ambrosio, R.; Degasperi, E.; Lampertico, P. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. J. Hepatocell. Carcinoma 2021, 8, 713–739. [Google Scholar] [CrossRef]
  6. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018, 68, 723–750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Ioannou, G.N.; Beste, L.A.; Green, P.K.; Singal, A.G.; Tapper, E.B.; Waljee, A.K.; Sterling, R.K.; Feld, J.J.; Kaplan, D.E.; Taddei, T.H.; et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology 2019, 157, 1264. [Google Scholar] [CrossRef] [Green Version]
  8. Watanabe, T.; Tokumoto, Y.; Joko, K.; Michitaka, K.; Horiike, N.; Tanaka, Y.; Tada, F.; Kisaka, Y.; Nakanishi, S.; Yamauchi, K.; et al. Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection. J. Med. Virol. 2020, 92, 3507–3515. [Google Scholar] [CrossRef]
  9. Guidance, A.-I.H.C. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020, 71, 686–721. [Google Scholar] [CrossRef] [Green Version]
  10. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. 2018, 69, 461–511. [Google Scholar] [CrossRef] [Green Version]
  11. Kozumi, K.; Kodama, T.; Murai, H.; Sakane, S.; Govaere, O.; Cockell, S.; Motooka, D.; Kakita, N.; Yamada, Y.; Kondo, Y.; et al. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology 2021, 74, 2452–2466. [Google Scholar] [CrossRef] [PubMed]
  12. Adams, J.C.; Lawler, J. The thrombospondins. Cold Spring Harb. Perspect. Biol. 2011, 3, a009712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Lee, C.H.; Seto, W.K.; Lui, D.T.; Fong, C.H.; Wan, H.Y.; Cheung, C.Y.; Chow, W.S.; Woo, Y.C.; Yuen, M.F.; Xu, A.; et al. Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. Diabetes Care 2021, 44, 2089–2097. [Google Scholar] [CrossRef] [PubMed]
  14. Kimura, T.; Tanaka, N.; Fujimori, N.; Yamazaki, T.; Katsuyama, T.; Iwashita, Y.; Pham, J.; Joshita, S.; Pydi, S.P.; Umemura, T. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver Int. 2021, 41, 505–514. [Google Scholar] [CrossRef] [PubMed]
  15. Rinaldi, L.; Nevola, R.; Franci, G.; Perrella, A.; Corvino, G.; Marrone, A.; Berretta, M.; Morone, M.V.; Galdiero, M.; Giordano, M.; et al. Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. Cancers 2020, 12, 1351. [Google Scholar] [CrossRef] [PubMed]
  16. Ioannou, G.N.; Green, P.; Lowy, E.; Mun, E.J.; Berry, K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE 2018, 13, e0204412. [Google Scholar] [CrossRef] [Green Version]
  17. Zou, H.; Yang, X.; Li, Q.L.; Zhou, Q.X.; Xiong, L.; Wen, Y. A Comparative Study of Albumin-Bilirubin Score with Child-Pugh Score, Model for End-Stage Liver Disease Score and Indocyanine Green R15 in Predicting Posthepatectomy Liver Failure for Hepatocellular Carcinoma Patients. Dig. Dis. 2018, 36, 236–243. [Google Scholar] [CrossRef]
  18. Vergniol, J.; Foucher, J.; Terrebonne, E.; Bernard, P.H.; Le Bail, B.; Merrouche, W.; Couzigou, P.; de Ledinghen, V. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011, 140, 1970–1979. [Google Scholar] [CrossRef]
  19. Kanwal, F.; Kramer, J.R.; Mapakshi, S.; Natarajan, Y.; Chayanupatkul, M.; Richardson, P.A.; Li, L.; Desiderio, R.; Thrift, A.P.; Asch, S.M.; et al. Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease. Gastroenterology 2018, 155, 1828–1837.e2. [Google Scholar] [CrossRef] [Green Version]
  20. Tahata, Y.; Sakamori, R.; Yamada, R.; Kodama, T.; Hikita, H.; Hagiwara, H.; Imai, Y.; Hiramatsu, N.; Tamura, S.; Yamamoto, K.; et al. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment. Pharmacol. Ther. 2021, 54, 1340–1349. [Google Scholar] [CrossRef]
  21. Tamaki, N.; Kurosaki, M.; Yasui, Y.; Mori, N.; Tsuji, K.; Hasebe, C.; Joko, K.; Akahane, T.; Furuta, K.; Kobashi, H.; et al. Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatol. Commun. 2022, 6, 461–472. [Google Scholar] [CrossRef] [PubMed]
  22. Kanwal, F.; Kramer, J.; Asch, S.M.; Chayanupatkul, M.; Cao, Y.; El-Serag, H.B. Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents. Gastroenterology 2017, 153, 996–1005.e1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Farhang Zangneh, H.; Wong, W.W.L.; Sander, B.; Bell, C.M.; Mumtaz, K.; Kowgier, M.; van der Meer, A.J.; Cleary, S.P.; Janssen, H.L.A.; Chan, K.K.W.; et al. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients with Hepatitis C Virus Infection and Advanced Fibrosis. Clin. Gastroenterol. Hepatol. 2019, 17, 1840–1849.e16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Semmler, G.; Meyer, E.L.; Kozbial, K.; Schwabl, P.; Hametner-Schreil, S.; Zanetto, A.; Bauer, D.; Chromy, D.; Simbrunner, B.; Scheiner, B.; et al. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J. Hepatol. 2022, 76, 812–821. [Google Scholar] [CrossRef]
  25. Cabral, L.K.D.; Grisetti, L.; Pratama, M.Y.; Tiribelli, C.; Pascut, D. Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers 2022, 14, 2700. [Google Scholar] [CrossRef]
  26. Nagata, H.; Nakagawa, M.; Asahina, Y.; Sato, A.; Asano, Y.; Tsunoda, T.; Miyoshi, M.; Kaneko, S.; Otani, S.; Kawai-Kitahata, F.; et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J. Hepatol. 2017, 67, 933–939. [Google Scholar] [CrossRef]
  27. Bekki, Y.; Yoshizumi, T.; Shimoda, S.; Itoh, S.; Harimoto, N.; Ikegami, T.; Kuno, A.; Narimatsu, H.; Shirabe, K.; Maehara, Y. Hepatic stellate cells secreting WFA(+) -M2BP: Its role in biological interactions with Kupffer cells. J. Gastroenterol. Hepatol. 2017, 32, 1387–1393. [Google Scholar] [CrossRef]
  28. Debes, J.D.; van Tilborg, M.; Groothuismink, Z.M.A.; Hansen, B.E.; Schulze Zur Wiesch, J.; von Felden, J.; de Knegt, R.J.; Boonstra, A. Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated with Direct-Acting Antivirals. Gastroenterology 2018, 154, 515–517.e3. [Google Scholar] [CrossRef]
  29. Myojin, Y.; Hikita, H.; Tahata, Y.; Doi, A.; Kato, S.; Sasaki, Y.; Shirai, K.; Sakane, S.; Yamada, R.; Kodama, T.; et al. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment. Pharmacol. Ther. 2022, 55, 422–433. [Google Scholar] [CrossRef]
Cancers 15 00463 g001 550
Figure 1. Serum TSP-2 levels can be used to identify CHC patients who have a high risk of HCC development after HCV elimination by DAA treatment. (A) Kaplan–Meier curve for HCC occurrence in the derivation cohort. (B) Serum TSP-2 levels in the HCC+ group and HCC− group in the derivation cohort. (C) ROC curve of TSP-2 for HCC occurrence in the derivation cohort. (D) Kaplan–Meier curves for the occurrence of HCC in patients in the derivation cohort divided by the TSP-2 Youden index level of 86.954 ng/µL.
Figure 1. Serum TSP-2 levels can be used to identify CHC patients who have a high risk of HCC development after HCV elimination by DAA treatment. (A) Kaplan–Meier curve for HCC occurrence in the derivation cohort. (B) Serum TSP-2 levels in the HCC+ group and HCC− group in the derivation cohort. (C) ROC curve of TSP-2 for HCC occurrence in the derivation cohort. (D) Kaplan–Meier curves for the occurrence of HCC in patients in the derivation cohort divided by the TSP-2 Youden index level of 86.954 ng/µL.
Cancers 15 00463 g001
Cancers 15 00463 g002 550
Figure 2. Serum TSP-2 levels reflect liver fibrosis and inflammation in CHC patients after HCV elimination by DAA treatment. (A) TSP-2 levels by fibrosis stage in the derivation cohort. (B–D) Correlation between TSP-2 levels and HA (B), AST (C), and ALT (D) in the derivation cohort.
Figure 2. Serum TSP-2 levels reflect liver fibrosis and inflammation in CHC patients after HCV elimination by DAA treatment. (A) TSP-2 levels by fibrosis stage in the derivation cohort. (B–D) Correlation between TSP-2 levels and HA (B), AST (C), and ALT (D) in the derivation cohort.
Cancers 15 00463 g002
Cancers 15 00463 g003 550
Figure 3. The AFT score composed of AFP, TSP-2 and FIB-4 index stratifies patients according to the HCC risk after DAA treatment. (A,B) ROC curves of AFP (A) and FIB-4 index (B) for HCC occurrence in the derivation cohort. (C) ROC curves and the AUROCs of AFP, FIB-4 index, TSP-2 and AFT score in the derivation cohort. (D) Kaplan–Meier curves for the occurrence of HCC in patients in the derivation cohort stratified by the AFT score.
Figure 3. The AFT score composed of AFP, TSP-2 and FIB-4 index stratifies patients according to the HCC risk after DAA treatment. (A,B) ROC curves of AFP (A) and FIB-4 index (B) for HCC occurrence in the derivation cohort. (C) ROC curves and the AUROCs of AFP, FIB-4 index, TSP-2 and AFT score in the derivation cohort. (D) Kaplan–Meier curves for the occurrence of HCC in patients in the derivation cohort stratified by the AFT score.
Cancers 15 00463 g003
Cancers 15 00463 g004 550
Figure 4. The TSP-2 and AFT scores stratified patients according to HCC risk in the validation cohort. (A) Kaplan–Meier curve for HCC occurrence. (B) Serum TSP-2 levels in the HCC+ group and HCC− group. (C) Kaplan–Meier curves for the occurrence of HCC in patients stratified by serum TSP-2 levels. (D) Kaplan–Meier curves for the occurrence of HCC in patients stratified by the AFT score.
Figure 4. The TSP-2 and AFT scores stratified patients according to HCC risk in the validation cohort. (A) Kaplan–Meier curve for HCC occurrence. (B) Serum TSP-2 levels in the HCC+ group and HCC− group. (C) Kaplan–Meier curves for the occurrence of HCC in patients stratified by serum TSP-2 levels. (D) Kaplan–Meier curves for the occurrence of HCC in patients stratified by the AFT score.
Cancers 15 00463 g004
Cancers 15 00463 g005 550
Figure 5. The serum TSP-2 level identifies patients with a high risk of HCC occurrence among patients with a FIB-4 index < 3.25. Kaplan–Meier curves for the occurrence of HCC in patients with a FIB-4 index less than 3.25 among all the cohorts stratified by serum TSP-2 levels.
Figure 5. The serum TSP-2 level identifies patients with a high risk of HCC occurrence among patients with a FIB-4 index < 3.25. Kaplan–Meier curves for the occurrence of HCC in patients with a FIB-4 index less than 3.25 among all the cohorts stratified by serum TSP-2 levels.
Cancers 15 00463 g005
Table
Table 1. Characteristics of patients in the derivation cohort.
Table 1. Characteristics of patients in the derivation cohort.
FactorUnitAll (N = 524)Missing (N)Non HCC (N = 500)HCC (N = 24)p Value
AgeYears Old70 (62–77)070 (61–76)71 (65–79)0.171
SexMale/Female204/3200192/30812/120.255
HCV Group1/2/Other406/117/10386/113/120/4/00.771
HCV-RNA(Pre)Log IU/mL6.2 (5.6–6.5)26.2 (5.6–6.5)6.2 (5.4–6.6)0.976
BMI(Pre)kg/m222.4 (20.4–24.3)2922.4 (20.4–24.3)22.9 (20.6–26.0)0.322
WBC/μL4700 (3890–5680)484700 (3900–5690)4290 (3530–5650)0.409
Hbg/dL13.1 (12.0–14.2)4813.1 (12.0–14.2)12.2 (10.7–13.7)0.071
Plt×104/μL16.8 (13.4–20.9)116.9 (13.5–21.0)13.8 (10.4–20.0)0.046
ASTU/L23 (19–28)123 (19–28)27 (24–34)0.083
ALTU/L17 (12–24)117 (12–24)20 (15–27)0.367
T-bilmg/dL0.7 (0.6–1.0)10.7 (0.6–1.0)0.8 (0.6–1.0)0.030
eGFRmL/min/1.73 m268.9 (60–80)4869 (60–80)66.3 (60.9–80.4)0.742
CRPmg/dL0.1 (0.02–0.1)1130.1 (0.02–0.1)0.1 (0.05–0.1)0.149
HbA1c%5.5 (5.2–5.9)755.5 (5.2–5.9)5.3 (5.0–5.8)0.725
Albg/dL4.1 (3.9–4.3)84.1 (3.9–4.3)4.0 (3.7–4.2)0.011
Hyaluronic Acidng/mL84 (39–163)18481 (38–156)149 (103–339)0.031
AFPng/mL4.0 (2.7–5.9)164.0 (2.6–5.5)6.0 (3.3–10)<0.0001
DCPmAU/mL18 (14–21)16018 (14–21)16 (11–20)0.386
FIB-4 index 2.3 (1.7–3.2)12.3 (1.6–3.2)3.5 (2.4–4.3)0.0007
TSP-2ng/μL44.9 (29.0–72.4)044.2 (28.3–71.2)78.2 (44.1–111)<0.0001
Abbreviations: HCC, hepatocellular carcinoma; HCV, hepatitis C virus; RNA, ribonucleic acid; BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; Plt, platelet; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-bil, total bilirubin; eGFR, estimated glomerular filtration rate; CRP, c-reactive protein; HbA1c, hemoglobin A1c; Alb, albumin; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; FIB-4, fibrosis-4; TSP-2, thrombospondin-2.
Table
Table 2. Univariate and multivariate analysis in the derivation cohort.
Table 2. Univariate and multivariate analysis in the derivation cohort.
FactorUnitUnivariate Analysis p ValueMultivariate Analysis p Value
AgeYears Old0.175
Sex 0.244
HCV Group 0.700
HCV-RNA(Pre)Log IU/mL0.981
BMI(Pre)kg/m20.369
WBC/μL0.412
Hbg/dL0.078
Plt×104/μL0.056
ASTU/L0.106
ALTU/L0.343
T-bilmg/dL0.042
eGFRmL/min/1.73 m20.723
CRPmg/dL0.228
HbA1c%0.740
Albg/dL0.011
Hyaluronic Acidng/mL0.109
AFPng/mL<0.0001<0.0001
DCPmAU/mL0.399
FIB-4 index 0.0060.015
TSP-2ng/μL0.00020.003
Abbreviations: HCV, hepatitis C virus; RNA, ribonucleic acid; BMI, body mass index; WBC, white blood cell; Hb, hemoglobin; Plt, platelet; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T-bil, total bilirubin; eGFR, estimated glomerular filtration rate; CRP, c-reactive protein; HbA1c, hemoglobin A1c; Alb, albumin; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin; FIB-4, fibrosis-4, TSP-2, thrombospondin-2.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Matsumae, T.; Kodama, T.; Tahata, Y.; Myojin, Y.; Doi, A.; Nishio, A.; Yamada, R.; Nozaki, Y.; Oshita, M.; Hiramatsu, N.; et al. Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral. Cancers 2023, 15, 463. https://doi.org/10.3390/cancers15020463

AMA Style

Matsumae T, Kodama T, Tahata Y, Myojin Y, Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, et al. Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral. Cancers. 2023; 15(2):463. https://doi.org/10.3390/cancers15020463

Chicago/Turabian Style

Matsumae, Takayuki, Takahiro Kodama, Yuki Tahata, Yuta Myojin, Akira Doi, Akira Nishio, Ryoko Yamada, Yasutoshi Nozaki, Masahide Oshita, Naoki Hiramatsu, and et al. 2023. "Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral" Cancers 15, no. 2: 463. https://doi.org/10.3390/cancers15020463

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop